5302392026-04-012026-06-305302392026-06-305302392026-04-012026-06-30in-capmkt:OtherExpenses1Member5302392026-04-012026-06-30in-capmkt:OtherExpenses2Member5302392026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15302392026-06-30Statement15302392026-04-012026-06-30Statement15302392026-06-30StatementDynamic1I1Statement15302392026-06-30StatementDynamic1I2Statement15302392026-06-30StatementDynamic1I3Statement15302392026-06-30StatementDynamic1I4Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares530239SUVENNOTLISTEDINE495B01038SUVEN LIFE SCIENCES LIMITEDMain BoardEquity2026-04-012027-03-312026-08-062026-07-30INRLakhsQuarterlyFirst quarterSingle segmentThe Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented2026-08-0611:30:002026-08-0612:30:00Not applicabletrue1falseNil2026-04-012026-06-30UnauditedStandalone356580007523600011089400000072818000476100021551000172955000272085000-1611910000-1611910000000-1611910000000-161191000-555000-1617460002639930001-0.61-0.6100-0.61-0.611. The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 06, 2026. The financial results for the quarter ended June 30, 2026 has been reviewed by our statutory auditors and issued unmodified reports thereon. <br /> 2. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. <br /> 3. The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences, Inc. <br /> 4. The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. <br /> 5.1 The Company implemented SLSL Employee Stock Option Scheme 2020 ("ESOP") for eligible employees, 1,33,200 stock options were granted on May 13,2026 by the Nomination & Remuneration Committee. <br /> 5.2 ESOP: for the quarter ended June 30, 2026, the Company has recognized an employee benefit expense (EBP) of Rs. 145.54 lakhs in accordance with Ind AS 102 – Share-based Payment. <br /> 5.3 During the quarter ended June 30, 2026, the Company has allotted 2,71,970 equity shares of Rs.1 each, pursuant to the exercise of stock options by the employees of the company under Employee Stock Options Scheme 2020. <br /> 6. Preferential Issue: The Board of Directors of the Company has approved the issue of 6,40,02,999 convertible warrants on a preferential basis to 23 allottees in its meeting held on 13th May, 2025, in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Subsequently, shareholders of the Company approved the issue of convertible warrants in their meeting held on 05th June, 2025. <br /> Each warrant is convertible into one equity share of face value Rs.1 at an exercise price of Rs.134 per share, within a period of 18 months from the date of allotment. <br /> As on 30 June 2026, the company has received the entire amount of Rs.85,764.02 lakhs from the warrant holders, out of which an amount of Rs.9,331.49 lakhs was received during the quarter in respect of 1,85,70,133 warrants, for which allotment is pending as on reporting date. <br /> Summary of Utilisation of Proceeds of Preferential issue as on 30.06.2026 <br /> Particulars Amount Rs. in Lakhs <br /> Amount Received through Preferential Issue 85,764.02 <br /> Less: Amount Utilised 40,950.29 <br /> Balance Amount 44,813.73 <br /> 7. The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to third quarter of the financial year.R & D Expenses127560000Other Expenses45395000Items that will not be reclassified to profit or loss-555000-55500000-555000Preferential Issues2025-07-0385764020002026-06-30trueCRISIL Ratings LimitedfalseNot ApplicableNilNot ApplicableM. Mohan KumarChief Financial OfficerHyderabad2026-08-06Expenses towards the conduct of clinical development of molecules in research pipeline through Suven Neurosciences, Inc. an overseas wholly owned subsidiary of the CompanyNot Applicable4000000000027242870000The difference amount (Original Allocation - Funds Utilised) of Rs. 12,757.13 is yet to be utilized as on 30-06-2026Expenses towards Drug Discovery Research & Development (R&D)Not Applicable130000000005187230000The difference amount (Original Allocation - Funds Utilised) of Rs. 7,812.77 is yet to be utilized as on 30-06-2026Expenses towards new R&D Centre with all requisite infrastructure and equipments (CAPEX)Not Applicable200000000004960940000The difference amount (Original Allocation - Funds Utilised) of Rs. 15,039.06 is yet to be utilized as on 30-06-2026Expenses towards General Corporate purposesNot Applicable127640200003559240000The difference amount (Original Allocation - Funds Utilised) of Rs. 9,204.78 is yet to be utilized as on 30-06-2026